Navigation Links
SuperGen Reports 2008 First Quarter Financial Results
Date:4/28/2008

erlotinib resistance on HER-family tyrosine kinases

by combination with MP-470, a multi-targeted TK inhibitor in

prostate and breast cancer," highlighted data indicating that the

combination of MP-470 and erlotinib inhibits the binding of the p85

subunit of PI3K. The poster outlined the enhanced impact of the

combination of MP-470 and erlotinib, compared to either agent alone

in reducing phosphorylation of Akt, ERK1/2, EGFR/HER1, HER2/Neu, and

HER3.

-- S-110, a DNA methyltransferase inhibitor, demonstrated an improved

in vivo efficacy profile over decitabine (Abstract No. 2613). The

presentation entitled, "Decitabine administered as a Dinucleotide

prodrug increases its in vivo efficacy due to enhanced drug delivery

and stability," highlighted data indicating that S-110 showed robust

anti-tumor activity in prostate and cisplatin-resistant ovarian

carcinoma xenograft models. Additionally, S-110 restored sensitivity

to cisplatin in the ovarian cancer model. Reduced toxicity was

observed along with an increased half-life compared to decitabine.

Conference Call Information

SuperGen will host a conference call to discuss the results of the 2008 first quarter financial results today at 1:30 p.m. PT / 4:30 p.m. ET. A live webcast of the conference call is accessible via the investor relations section of the Company's web site at http://ir.supergen.com. A webcast replay of the conference call will be available for 90 days.

About SuperGen

Based in Dublin, California, SuperGen, Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused
'/>"/>

SOURCE SuperGen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
2. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
3. SuperGen to Announce 2007 Fourth Quarter and Fiscal Year-End Financial Results March 3, 2008
4. SuperGen Reports 2007 Fourth Quarter and Annual Financial Results
5. SuperGen to Announce 2008 First Quarter Financial Results April 28, 2008
6. SuperGen to Webcast 3rd Annual Analyst Day on April 29, 2008
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. QMed, Inc. Reports July Medicare SNP Enrollments
9. Phlo Affiliate Reports Expanded Coverage to Oregon Border
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 /PRNewswire-iReach/ -- Tute Genomics, the ... announced an agreement with Lineagen, Inc., to ... NextStep Dx PLUS.  Lineagen, focused on ... disorders, currently offers FirstStep Dx PLUS, ... used by healthcare providers as a first-line ...
(Date:7/10/2014)... April 15, 2014 -- According to the International ... nuclear security comes from terrorists acquiring sufficient quantities ... construct a crude nuclear explosive device. The IAEA ... trafficking have involved gram-level quantities, which can be ... According to a new study appearing this week ...
(Date:7/10/2014)... in the journal PNAS (Proceedings of the National ... day and sleep deprivation have a significant effect on ... at the best time of day to test for ... administering medicines effectively. , Researchers from the University of ... the links between sleep deprivation, body clock disruption and ...
(Date:7/10/2014)... The lithium-ion batteries that power our laptops and ... on a single charge with the help of a ... material to replace the graphite traditionally used in one ... 10 times the energy storage capacity of graphite. A ... electrode was published today in Nature Communications . ...
Breaking Biology Technology:Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Sensitive detection method may help impede illicit nuclear trafficking 2Time of day crucial to accurately test for diseases, new research finds 2Silicon sponge improves lithium-ion battery performance 2Silicon sponge improves lithium-ion battery performance 3
... weeks back, we took a look at the results of the ... that time, we saw that the Midwest had two states in the ... the top 20 states. I promised to circle back with you to ... the Midwest fared in this ranking. , ,The NIH falls under ...
... slowly getting over its shyness about asking for federal ... business executives is learning more about how ... Business Technology Transfer Conference at the Hilton Milwaukee ... programs, one (SBIR) designed to foster small business innovation, ...
... - Angel and venture investors have fewer secrets ... dispense some advice to early-stage executives during the National ... with scientific ties to the University of Wisconsin-Madison ... their products have a sustainable market advantage, and what ...
Cached Biology Technology:Midwest colleges strong contenders for NIH funds 2Midwest colleges strong contenders for NIH funds 3Midwest colleges strong contenders for NIH funds 4Midwest colleges strong contenders for NIH funds 5Wisconsin firms urged to pursue federal SBIR dollars 2Wisconsin firms urged to pursue federal SBIR dollars 3Early-stage executives hear from investors 2Early-stage executives hear from investors 3
(Date:7/11/2014)... mesenchymal stem cells can stimulate neurogenesis in the brain ... (AD) and improve tissue and function injury under the ... the therapeutic effect of adipose-derived stem cells (ADSCs) transplantation ... oxidative injury and neurogenesis in the brain of AD ... Life Sciences, Tsinghua University, China transplanted ADSCs into the ...
(Date:7/11/2014)... toxins to study the proteins that let nerve cells ... have stumbled upon a biological tactic that may offer ... in a safe and environmentally responsible way. , ... for one species and harmless for a closely related ... pests without harming beneficial species like bees. A summary ...
(Date:7/10/2014)... BEDFORD, Mass. , June 30, 2014  Aware, ... of biometrics software and services, previously announced on June ... a special cash dividend of $1.75 per share, or ... record date of July 10, 2014 and a payment ... notified by NASDAQ that it had set an ex-dividend ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2
... This release is available in French . ... the Minister of Industry, on behalf of the Honourable ... the Natural Sciences and Engineering Research Council of Canada ... announced that Nobel Laureate John C. Polanyi is the ...
... have a sizeable biofuels industry based primarily on local ... and new conversion technologies are used, according to a ... Northwest National Laboratory. It will be difficult ... based on todays land use practices with currently available ...
... WINSTON-SALEM, N.C. A small group of patients with ... veins with an injectable microfoam experienced no neurological, visual ... according to preliminary results from a phase II trial. ... Washington, D.C., at the annual scientific meeting of the ...
Cached Biology News:Dr. John Polanyi wins Canada's most prestigious science award 2Key to using local resources for biomass may include waste 2Key to using local resources for biomass may include waste 3Improved foam for varicose veins found to be safe in preliminary results from phase II trial 2
Dual-bay Dyad thermal cycler chassis, does not include the Alpha units (requires 2)...
... dual-bay DNA Engine Dyad thermal cycler ... amplification (PCR). The chassis accommodates a ... heat-pump assemblies), which hold different types ... offers graphical programming with point-and-click navigation. ...
... Red fluorescent RNA stain is used to ... or glyoxal) agarose gels and does not ... a 302 nm transilluminator, the stain emits ... on Polaroid film or with a CCD ...
... The MitoPT kit is used in conjunction ... in culture and induce apoptosis according to your ... cells as a negative control). Once you have ... MitoPT solution to each population and incubate the ...
Biology Products: